2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Treatment Considerations, Biological Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Biological Processes, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Genetic Disorders, Immunology, Autoimmune Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

5578 A reversible stemness state links STAG2-mutant MDS to AML transformation

Jane J. Xu, PhD, Yi Chen, MD, PhD2, John Pantazi3, Sebastian Fernando, MS4, Besmira Alija5, Varun Saichandan Sudunagunta, B.A.6, Martin Carroll, MD7, Robert L Bowman, PhD8, Aaron Viny, MD, MS9
1 Columbia Stem cell Inititative, New York City, New York, United States, Department of Medicine, Hematology-Oncology, New York, New York, United States
2 Columbia Stem cell Inititative, New York City, New York, United States, Department of Medicine, Hematology-Oncology, New York, New York, United States
3 Columbia Stem cell Inititative, New York City, New York, United States, Department of Medicine, Hematology-Oncology, New York, New York, United States
4 Columbia Stem cell Inititative, New York City, New York, United States, Department of Medicine, Hematology-Oncology, New York, New York, United States
5 Columbia Stem cell Inititative, New York City, New York, United States, Department of Medicine, Hematology-Oncology, New York, New York, United States
6 Columbia Stem cell Inititative, New York City, New York, United States, Vagelos College of Physicians and Surgeons, New York City, New York, United States
7 Perelman School of Medicine, Philadelphia, Pennsylvania, United States
8 Department of Cancer Biology, Philadelphia, Pennsylvania, United States
9 Columbia Stem cell Inititative, New York City, New York, United States, Department of Medicine, Hematology-Oncology, New York, New York, United States, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York City, New York, United States

Transformation to acute myeloid leukemia (AML) is a catastrophic event for patients with myelodysplastic syndromes (MDS) and defines a distinct entity, AML with myelodysplasia-related changes (AML-MR). AML-MR is separated from de novo AML by antecedent disease history, a characteristic set of mutations (SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, STAG2), and chromosomal abnormalities shared with MDS. Although the trajectory is clear, the mechanistic basis of transformation remains poorly understood, and no strategy exists to prevent it. Intercepting it requires an integrated understanding of both diseases and faithful pre-clinical models. STAG2, a core cohesin subunit, is the most frequently mutated 3D genome organizer and is among the MR genes mutated at the MDS stage. Our laboratory has shown that STAG2-cohesin is a key regulator of HSPC lineage commitment, a function dysregulated in MDS.

We hypothesized that STAG2 mutation establishes a transformation-permissive stemness state during MDS that persists after leukemic transformation and constitutes a therapeutic vulnerability. To model MDS-to-AML transformation, we induced Stag2 and Flt3-ITD mutations sequentially, at physiological levels and without transplantation, allowing disease to evolve in a native setting. We activated Stag2 via Mx1-Cre to initiate the MDS phase and, 16 weeks later, Flt3-ITD via R26-FlpoERT2; Stag2/Flt3 mice were monitored through a 16-week transformation phase. At the endpoint, a phenotypically and transcriptomically defined hematopoietic stem cell (HSC) population was preserved in Stag2/Flt3 AML but absent in Flt3 single-mutant AML, indicating persistence of stem-cell identity despite transformation. HSC expansion was already evident in Stag2 single-mutant mice before Flt3 activation, identifying Stag2 loss as the primary driver of this phenotype. To test their function, we competitively transplanted MDS-phase marrow and activated Flt3 in vivo. Both Flt3 and Stag2/Flt3 marrow outcompeted wild-type marrow, confirming the functional fitness of transformed hematopoiesis and persistence of the Stag2-associated stem-cell advantage.

Unlike de novo AML, AML-MR arises from dysplastic hematopoietic stem and progenitor cells (HSPCs) rather than from normal stem cells. We therefore asked whether STAG2 loss shapes the stem-cell phenotype of human AML. We performed scRNA-seq on blasts from 12 AML samples (3 STAG2-mutant, 3 FLT3-mutant, 6 STAG2/FLT3-mutant), annotated cell populations using the bone marrow reference map, and compared HSPC (HSC, MPP, LMPP) abundance against STAG2 variant allele frequency (VAF). HSPC abundance in blasts increased with STAG2 VAF (R = 0.57), with no such correlation for FLT3-ITD (R = 0.067). GSEA of STAG2/FLT3 versus FLT3 AML showed enrichment of stemness, cell-cycle, and proliferative programs (NES +2.04, padj 3.7e-5) and reciprocal suppression of differentiation-associated pathways (NES −2.38, padj 4.6e-7). The human signature recapitulated the phenotype seen in our murine model, identifying STAG2 rather than FLT3 as the driver of a transformation-permissive stemness state conserved across species and disease stages.

Persistence across disease stages defines a therapeutic window in which leukemic evolution might be intercepted before overt leukemia develops. To ask whether the state is reversible, we developed a model permitting restoration of STAG2 expression and function in mutant cells. After restoration, scRNA-seq of lineage-negative HSPCs showed suppression of E2F- (NES +2.80, padj 4.6e-18) and G2M-associated programs (NES +2.51, padj 1.0e-20) alongside restored myeloid and lymphoid differentiation. These transcriptional changes were accompanied by contraction of the stem and progenitor compartment and functional recovery of differentiation, including decreased Lin− cKit+ Sca1+ cells and restored differentiation after transplantation.

Together, these studies identify a persistent but reversible transformation-permissive stemness state as the biological link between STAG2-mutant MDS and AML. The state originates before transformation, persists after acquisition of cooperating oncogenic mutations, and is evident in human AML. Restoration of STAG2 function extinguishes the stemness program, contracts mutant clones, and restores differentiation, indicating that AML evolution is not inevitable and may be therapeutically intercepted by reversing STAG2-dependent stemness.

Jane J. Xu, PhD: No relevant conflicts of interest to declare.